Detalhe da pesquisa
1.
Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.
Ann Rheum Dis
; 83(2): 199-213, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793792
2.
Goodbye to the term 'ankylosing spondylitis', hello 'axial spondyloarthritis': time to embrace the ASAS-defined nomenclature.
Ann Rheum Dis
; 83(5): 547-549, 2024 Apr 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071514
3.
Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
Ann Rheum Dis
; 82(4): 515-526, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36649967
4.
Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.
Rheumatology (Oxford)
; 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37947318
5.
The faecal microbiota is distinct in HLA-B27+ ankylosing spondylitis patients versus HLA-B27+ healthy controls.
Clin Exp Rheumatol
; 41(5): 1096-1104, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441657
6.
Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort.
Rheumatology (Oxford)
; 61(5): 2079-2087, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427579
7.
Ixekizumab in radiographic axial spondyloarthritis with and without elevated C-reactive protein or positive magnetic resonance imaging.
Rheumatology (Oxford)
; 61(11): 4324-4334, 2022 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35188180
8.
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Ann Intern Med
; 174(11): 1572-1585, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34461029
9.
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Lancet
; 395(10217): 53-64, 2020 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31813637
10.
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Ann Rheum Dis
; 80(8): 1022-1030, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958326
11.
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Ann Rheum Dis
; 80(8): 1004-1013, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33906853
12.
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.
Ann Rheum Dis
; 80(9): 1168-1174, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161253
13.
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.
BMC Musculoskelet Disord
; 22(1): 1037, 2021 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34903218
14.
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Ann Rheum Dis
; 79(5): 595-604, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32253184
15.
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Ann Rheum Dis
; 79(2): 176-185, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685553
16.
Does psoriatic axial spondyloarthritis phenotype correlate with imaging morphotype?
Clin Exp Rheumatol
; 38(2): 329-332, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31577217
17.
A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values.
J Biopharm Stat
; 30(1): 160-177, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31730441
18.
Longitudinal associations between depressive symptoms and clinical factors in ankylosing spondylitis patients: analysis from an observational cohort.
Rheumatol Int
; 40(7): 1053-1061, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32166439
19.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Lancet
; 392(10162): 2378-2387, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360970
20.
HLA class I and II alleles in susceptibility to ankylosing spondylitis.
Ann Rheum Dis
; 78(1): 66-73, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30341055